Effect of Dapagliflozin on cardiac function，inflammatory response and cardiovascular outcomes in patients with unstable angina pectoris and type 2 diabetes after percutaneous coronary intervention
ZHANG Gang
Department of Cardiology,Liaoyang Central Hospital,Liaoning Province,Liaoyang 111000,China
Abstract：Objective To explore the effect of Dapagliflozin on cardiac function,inflammatory response and cardiovascular outcome in patients with unstable angina(UA)combined with type 2 diabetes(T2DM)after percutaneous coronary intervention(PCI).Methods A total of 70 patients with UA combined with T2DM who underwent PCI in Liaoyang Central Hospital from September 2018 to September 2019 were selected as the research subjects,and they were divided into an observation group and a control group by random number table method,each with 35 cases.Both groups of patients were treated with conventional drugs.On this basis,patients in the observation group were treated with Dapagliflozin to control blood sugar and patients in the control group were treated with hypoglycemic drugs other than sodium-glucose cotransporter 2(SGLT-2)inhibitor.Both groups were treated continuously for 24 weeks.The differences in left ventricular end diastolic diameter(LVEDD),left ventricular end systolic diameter(LVESD),left ventricular ejection fraction(LVEF),inflammatory factor levels before and after treatment and major adverse cardiovascular events(MACE)between the two groups were analyzed.Results After treatment,LVEF of observation group was higher than that of control group,LVESD and LVEDD of observation group were lower than those of control group,the differences were statistically significant(P＜0.05).After treatment,the levels of C-reactive protein(CRP),interleukin 6(IL-6),tumor necrosis factor-α(TNF-α)of observation group were lower than those of the control group,the differences were statistically significant(P＜0.05).During the treatment period,there were no significant differences in the incidence rates of cardiogenic death,recurrent myocardial infarction and other adverse cardiovascular events between the two groups of patients(P＞0.05),but the incidence rates of severe arrhythmia and heart failure in the observation group were lower than those of the control group,the differences were statistically significant(P＜0.05).Conclusion Dapagliflozin treatment for patients with UA combined with T2DM after PCI can improve heart function to a certain extent,reduce the levels of inflammatory factors as well as the incidence of MACE.
张刚. 达格列净对不稳定心绞痛合并2型糖尿病患者冠脉介入治疗后心功能、炎症反应及心血管结局的影响[J]. 中国当代医药, 2022, 29(10): 57-61.
ZHANG Gang. Effect of Dapagliflozin on cardiac function，inflammatory response and cardiovascular outcomes in patients with unstable angina pectoris and type 2 diabetes after percutaneous coronary intervention. 中国当代医药, 2022, 29(10): 57-61.
McMurray JJV，Ponikowski P，Bolli GB.Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure：a randomized placebo-controlled trial[J].JACC Heart Fail，2018，6（1）：8-17.
[2]
Samman Tahhan A，Sandesara P，Hayek SS.High-Sensitivity Troponin I Levels and Coronary Artery Disease Severity，Progression，and Long-term Outcomes[J].JAm Heart Assoc，2018，7（5）：e007914.
[3]
Mishriky BM，Tanenberg RJ，Sewell KA.Cummings DM Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an addon therapy to metformin in patients with type 2 diabetes：A systematic review and meta-analysis[J].Diabetes Metab，2018，44（2）：112-120.
[4]
Harding SD，Sharman JL，Faccenda E.The IUPHAR/BPS Guide to PHARMACOLOGY in 2018：updates and expansion to encompass the new guide to IMMUNOPH ARMA COLOGY[J].Nucl Acids Res，2018，46（D1）：D1091-D1106
[5]
Neal B，Perkovic V，Mahaffey KW.Canagliflozin and cardiovascular and renal events in type 2 diabetes[J].N Engl J Med，2017，377（7）：644-657.
[6]
Ike A，Nishikawa H，Shiraik K，et al.Impact of glycemic control on the clinical outcome in diabetic patients with percutaneous coronary intervention-from the FU-registry[J].Circ J，2011，75（4）：791-799.
[7]
Accord Study Group，Gerstein HC，Miller ME，et al.Longterm effects of intensive glucose lowering on cardiovascular outcomes[J].N Engl J Med，2011，364（9）：818-828.
[8]
Leng W，Ouyang X，Lei X.The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE（-/-）mice[J].Mediators Inflamm，2016，26（2）：120-128.
[9]
Jabbour S，Seufert J，Scheen A，et al.Dapagliflozin in patients with type 2 diabetes mellitus：A pooled analysis of safety data from phase Ⅱb/Ⅲclinical trials[J].Diabetes Obes Metab，2018，20（3）：620-628.
[12]
Karavaglar E，Akgun AN，Muderrisoglu IH，et al.Coronary angiography for follow-up of heart transplant recipients：usefulness of the gensini score[J].Exp Clin Transplant，2020，18（S1）：99-104.
[13]
Everett BM，Brooks MM，Bhatt DL.Troponin in stable ischemic heart disease and diabetes[J].N Engl J Med，2015，373（20）：1978-1979.
[14]
Gaede P，Oellgaard J，Carstensen B.Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria：21 years follow-up on the Steno-2 randomised trial[J].Diabetologia，2016，59（11）：2298-2307.
[15]
Tancredi M，Rosengren A，Svensson AM.Excess mortality among persons with type 2 diabetes[J].N Engl J Med，2016，374（8）：788-789.
[16]
Scirica BM，Braunwald E，Raz I.Heart failure，saxagliptin，and diabetes mellitus：observations from the SAVOR-TIMI 53 randomized trial[J].Circulation，2014，130（18）：1579-1588.
[17]
Endler G，Klimesch A，Sunder-Plassmann H.Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease[J].Br J Haematol，2002，117（2）：399-404.
京公网安备 11010502046607号